6th Sep 2019 12:17
(Alliance News) - Nuformix PLC said on Friday it has appointed Muhunthan Thillai to its scientific advisory board with immediate effect.
Thillai is the lead clinician for the Cambridge Interstitial Lung Disease Unit, where he is also currently appointed as a consultant. The appointment reflects progress made with Nuformix's NXP002 programme as a treatment for idiopathic lung fibrosis, the company said.
Nuformix shares were up 11% at 7.685 pence in London on Friday.
Related Shares:
Nuformix